(Finance) – Illuminatea manufacturer of life science tools and systems for analyzing genetic variation, recorded enter of 1.16 billion dollars in second quarter of 2022, up 3% compared to the second quarter of 2021 and 5% at constant currency. There loss per share was $ 3.40 for Q2 2022, compared with earnings per share of $ 1.26 for Q2 2021. The loss includes a $ 609 million kickback in litigation. The results fell short of analysts’ expectations.
The society expects full-year revenue for fiscal year 2022 grow from 4% to 5% compared to fiscal year 2021, mainly reflecting the continuing negative impact of exchange rates, delays in the expansion of customer laboratories and the impacts of macroeconomic uncertainty. Expected loss per share $ 2.93 to $ 2.78 for fiscal year 2022.
“Our second quarter results they did not meet our expectations as challenges in a complex macroeconomic environment have more than offset the growth we continue to see in sequencing runs on our platforms, “he said Francis deSouzaCEO.